# Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

> **NCT04853368** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 48 (actual)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** ABBV-576
- **DRUG:** Galicaftor
- **DRUG:** Placebo
- **DRUG:** Navocaftor
- **DRUG:** ABBV-119

## Key facts

- **NCT ID:** NCT04853368
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-20
- **Primary completion:** 2023-06-05
- **Final completion:** 2023-06-05
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853368, "Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04853368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*